Published: 22 June 2024
Author(s): Adrián Martín-Gutiérrez, Javier Loricera, Javier Narváez, Vicente Aldasoro, Olga Maiz, Paloma Vela, Susana Romero-Yuste, Eugenio de Miguel, Eva Galíndez-Agirregoikoa, Jesús C. Fernández-López, Iván Ferraz-Amaro, Julio Sánchez-Martín, Patricia Moya, Cristina Campos, Fernando López-Gutiérrez, Santos Castañeda, Ricardo Blanco, Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group
Issue: July 2024
Section: Original Article

Giant Cell Arteritis (GCA) is a vasculitis involving the large and medium vessels, especially the extracranial branches of the carotid arteries, and particularly, the temporal artery. Arterial wall inflammation leads to luminal occlusion and tissue ischemia, which is responsible for the typical cranial clinical manifestations of the disease. GCA also involves the aorta and its major branches and sometimes lead to artery stenoses or even to aortic aneurysms, with the consequent risk of dissection, which usually causes high mortality [1–3].

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.